Markets India

Divi’s Laboratories shares surged to a 52-week high on 9 November 2026, driven by a 64% YoY rise in net profit to ₹1,127 crore and a 35% YoY revenue increase to ₹3,676 crore in Q2 FY27.

Divi's Laboratories Shares Surge 84% YTD to 52-Week High on Q2 FY27 Profit Jump

The pharmaceutical company’s strong Q2 FY27 results have sparked optimism among investors and brokerages, with shares hitting a record high after a 84% year-to-date rise. Net profit surged 64% to ₹1,127 crore, while revenue grew 35% to ₹3,676 crore, bolstered by a ₹24 crore foreign exchange gain in the quarter. Brokerages like Nuvama Institutional Equities and Goldman Sachs have raised their valuations, with Nuvama increasing its EV/EBITDA multiple to 44x and Goldman Sachs boosting FY27–FY29 EPS estimates by up to 17%. Motilal Oswal also raised earnings forecasts by 21% for FY27 and 19% for FY28, citing the company’s expansion into custom synthesis and peptides.

Divi’s Laboratories is positioning itself as a key player in the peptide manufacturing space, with its 3,000-litre solid-phase peptide synthesis (SPPS) lines enabling competition with peers like Wu Xi App Tec. Strong EBITDA margins of 42.6% in Q2 FY27 and operational leverage are seen as key drivers of profitability. However, risks remain, including pricing pressure in generics segments and potential delays from regulatory clearances for peptide projects. Analysts note that while the company’s innovation-led approach offers growth opportunities, current valuations may limit upside potential.

The stock’s rally reflects strong investor confidence in Divi’s growth trajectory, but the path forward depends on successful scaling of its peptide manufacturing capacity and navigating regulatory hurdles. As the company prepares to expand multi-tonne peptide production, its ability to convert validation-stage projects into commercial output will be critical to sustaining momentum.

Divi’s Laboratories plans to expand multi-tonne peptide manufacturing capacity via 3,000-litre SPPS reactors. Key milestones include regulatory clearances for remaining projects and the commercialization of validation-stage initiatives.

Divi’s Laboratories’ Q2 FY27 results and brokerages’ optimism have driven its stock to a record high, but valuations and regulatory outcomes remain key uncertainties.

Topics: Pharmaceuticals, Stock Markets, India, Brokerage Analysis, Custom Synthesis, Peptides, EBITDA, Financial Results

#DiviLaboratories #PharmaStocks #CustomSynthesis #Peptides #IndiaMarkets #BrokerageAnalysis

Source: LiveMint